Lactotripeptides for Blood Pressure: The Evidence
Dairy Bioactive Peptides
-3.73 mmHg systolic
A meta-analysis of clinical trials found that lactotripeptides IPP and VPP reduced systolic blood pressure by an average of 3.73 mmHg, but the effect was nearly six times larger in Asian populations than in European ones.
Cicero et al., J Human Hypertension, 2011
Cicero et al., J Human Hypertension, 2011
View as imageMilk contains hundreds of encrypted bioactive peptides that become active only after enzymatic digestion breaks apart the parent protein. Two of the most studied are Ile-Pro-Pro (IPP) and Val-Pro-Pro (VPP), tripeptides released from casein during fermentation or hydrolysis. These lactotripeptides inhibit angiotensin-converting enzyme (ACE), the same target as pharmaceutical ACE inhibitors like lisinopril and enalapril. As the pillar article on casomorphins and dairy peptides discusses, milk proteins generate a range of bioactive fragments. This article focuses specifically on the clinical trial data for lactotripeptides and blood pressure, because the evidence is more complicated than supplement marketing suggests.
Key Takeaways
- A meta-analysis of available clinical trials found lactotripeptides reduced systolic blood pressure by -3.73 mmHg and diastolic by -1.97 mmHg on average[1]
- The effect was dramatically population-dependent: -6.93 mmHg systolic in Asian subjects versus -1.17 mmHg in European subjects[1]
- In a placebo-controlled trial of 131 Japanese volunteers, casein hydrolysate containing VPP and IPP reduced systolic blood pressure by 5.2 mmHg over 12 weeks[2]
- VPP and IPP stimulate nitric oxide production in endothelial cells, suggesting a blood pressure mechanism beyond ACE inhibition[3]
- A 2025 randomized trial showed that a casein-derived ACE inhibitory peptide lowered blood pressure and reshaped gut microbiota composition[4]
- EFSA rejected health claims for lactotripeptides in 2012, stating the evidence was insufficient to establish a cause-and-effect relationship in the general European population
How IPP and VPP Inhibit ACE
Angiotensin-converting enzyme converts angiotensin I to angiotensin II, a potent vasoconstrictor that raises blood pressure. ACE also degrades bradykinin, a vasodilator. Inhibiting ACE therefore reduces vasoconstriction and preserves vasodilation, lowering blood pressure.
IPP and VPP inhibit ACE in vitro with IC50 values in the low micromolar range (approximately 5-9 microM for IPP, 9-32 microM for VPP). These values are far weaker than pharmaceutical ACE inhibitors (which work at nanomolar concentrations), but the tripeptides are consumed in milligram quantities through fermented milk products or supplements.
Saito (2008) reviewed the structural basis for ACE inhibition by casein-derived peptides and noted that the C-terminal proline-proline sequence in both IPP and VPP is critical for ACE binding[5]. The proline residue fits into the hydrophobic pocket of ACE's active site, competing with angiotensin I for enzyme access.
Yang et al. (2024) used molecular dynamics simulations to characterize the ACE-peptide interaction in detail[6]. They found that casein-derived ACE inhibitory peptides bind ACE through a combination of hydrogen bonding, hydrophobic interactions, and zinc coordination at the active site. The binding is reversible and competitive, meaning higher concentrations of angiotensin I can displace the peptide inhibitor.
The Meta-Analysis Evidence
Cicero et al. (2011) conducted the most comprehensive meta-analysis of lactotripeptide clinical trials[1]. Pooling data across available randomized controlled trials, they found:
Overall effect: Systolic blood pressure decreased by -3.73 mmHg (95% CI: -6.70 to -1.76) and diastolic by -1.97 mmHg (95% CI: -3.85 to -0.44).
Asian populations: SBP decreased by -6.93 mmHg, DBP by -3.98 mmHg. These effects are clinically meaningful and comparable to lifestyle interventions like dietary salt reduction.
European populations: SBP decreased by -1.17 mmHg, DBP by -0.52 mmHg. These effects are small and clinically marginal, barely distinguishable from placebo in most individual trials.
The population disparity is the central finding. The same peptides, at comparable doses, produced dramatically different results depending on the study population. Multiple explanations have been proposed: genetic differences in ACE polymorphisms, differences in baseline blood pressure, dietary context (Japanese diets are higher in sodium, which may amplify ACE inhibitor effects), and differences in gut peptidase activity affecting how much intact IPP/VPP reaches the bloodstream.
A separate meta-analysis of European trials specifically concluded that lactotripeptides do not lower ambulatory blood pressure in untreated white subjects. The Dutch trial that contributed most heavily to this conclusion (van der Zander et al., 2008) used ambulatory blood pressure monitoring over 24 hours, which is more rigorous than office blood pressure measurements used in most Japanese trials. The discrepancy between office and ambulatory blood pressure results adds another layer of complexity: some of the effect seen in Japanese trials may reflect a "white coat" response reduction rather than a true hemodynamic change.
EFSA cited this European evidence in rejecting health claims for lactotripeptide products in the European market in 2012. The regulatory conclusion was specific: the evidence does not support a claim that IPP and VPP help maintain normal blood pressure in the general European population. This does not mean the peptides are inactive; it means the clinical evidence does not meet the regulatory standard for a health claim in that specific population. The Japanese regulatory framework (FOSHU) has approved VPP/IPP-containing products with blood pressure claims based on the Japanese trial data.
Japanese Clinical Trials: Where the Data Is Strongest
The strongest individual trial evidence comes from Japan. Mizuno et al. (2005) enrolled 131 volunteers with high-normal blood pressure or mild hypertension in a single-blind, placebo-controlled study[2]. Subjects consumed a casein hydrolysate containing VPP and IPP daily for 12 weeks.
Results: systolic blood pressure decreased by 5.2 mmHg compared to baseline in the treatment group. The effect was statistically significant and clinically relevant. The casein hydrolysate was well tolerated with no reported adverse effects.
Hirota et al. (2007) demonstrated that casein hydrolysate containing VPP and IPP improved vascular endothelial function in addition to lowering blood pressure[7]. Specifically, the study measured flow-mediated dilation (FMD), a standard marker of endothelial health, and found improvement in subjects consuming the casein hydrolysate compared to placebo. This vascular protection effect suggests the tripeptides may benefit cardiovascular health through mechanisms beyond simple blood pressure reduction. Endothelial dysfunction precedes clinical hypertension by years, so a treatment that improves both blood pressure and endothelial function addresses two layers of cardiovascular risk.
The consistency of Japanese trial results is striking. Across multiple research groups, different casein hydrolysate preparations, and different study designs, the blood pressure reduction in Japanese subjects with mild hypertension clusters around 3-7 mmHg systolic. This replicability strengthens the conclusion that the effect is real in this population, even as the mechanism of action remains debated.
Beyond ACE Inhibition: The Nitric Oxide Pathway
Hirota et al. (2011) discovered that VPP and IPP directly stimulate nitric oxide (NO) production in cultured endothelial cells[3]. Nitric oxide is the primary vasodilator produced by the endothelial lining of blood vessels. By increasing NO, lactotripeptides may relax blood vessels independently of ACE inhibition.
This dual mechanism (ACE inhibition plus NO stimulation) could explain why lactotripeptides have cardiovascular effects that extend beyond what their modest ACE inhibitory potency would predict. The NO pathway may also contribute to the anti-atherosclerotic and endothelial-protective effects observed in some trials.
Wu et al. (2023) identified additional casein-derived peptides (specifically SQPK from goat beta-casein) that affect endothelial cell function through ACE inhibition and modulation of endothelial nitric oxide synthase expression[8]. The research suggests that the antihypertensive peptide pool from casein is larger than just IPP and VPP, and different peptides may act through partially overlapping mechanisms.
New Evidence: Gut Microbiota and Blood Pressure
Li et al. (2025) published a randomized trial examining casein-derived ACE inhibitory peptides (GPFPIIV and FFVAPFPEVFGK) and found that they not only lowered blood pressure but also reshaped gut microbiota composition[4]. The microbial shifts correlated with blood pressure changes, suggesting a gut-mediated pathway for antihypertensive effects.
This finding opens a new dimension in understanding how dairy-derived peptides affect blood pressure. If casein peptides modify gut bacteria that produce vasoactive metabolites, the blood pressure effect may be partly microbiome-mediated rather than purely enzymatic. This could also help explain population differences: gut microbiome composition varies between populations and correlates with diet, which may modulate how effectively casein peptides lower blood pressure.
Bioavailability: The Unresolved Question
A persistent criticism of lactotripeptide research is whether enough intact peptide survives digestion to reach the bloodstream at concentrations sufficient for ACE inhibition. IPP and VPP are tripeptides, vulnerable to degradation by gastrointestinal peptidases and brush border enzymes.
Some evidence suggests that proline-containing peptides are partially resistant to digestive proteolysis because many human peptidases cannot cleave the proline-proline bond efficiently. However, the fraction of intact peptide that reaches systemic circulation after oral intake is estimated at less than 1% of the ingested dose. At typical supplement doses (5-10 mg of IPP+VPP), the circulating concentration would be well below the IC50 for ACE inhibition in vitro.
This pharmacokinetic gap between in vitro ACE inhibitory potency and achievable plasma concentrations is one reason skeptics question whether ACE inhibition is truly the mechanism of action in vivo. The NO-stimulating pathway and gut microbiome effects may contribute more to the blood pressure response than direct ACE inhibition at the doses consumed.
An alternative hypothesis is that lactotripeptides act locally in the gut wall. The intestinal epithelium expresses ACE, and peptides transiting through the gut lumen could inhibit intestinal ACE before entering systemic circulation. Intestinal ACE participates in local angiotensin II production and fluid absorption, so inhibiting it could affect blood pressure through a gut-mediated pathway that does not require high systemic peptide concentrations. This hypothesis is consistent with the gut microbiome data from Li et al. (2025) and would explain how peptides with poor systemic bioavailability can still produce measurable cardiovascular effects.
Where the Evidence Stands
The clinical data for lactotripeptides divides cleanly along population lines. In Japanese populations, multiple well-conducted trials consistently show 3-7 mmHg systolic blood pressure reductions, which are clinically meaningful (a 5 mmHg reduction in systolic BP is associated with approximately 10% reduced stroke risk at the population level). In European populations, the effect is minimal and inconsistent.
This is not a failure of the science; it is a finding. The population-specific response tells us something about the biology. Possible explanations include genetic variation in ACE (the ACE I/D polymorphism varies significantly between East Asian and European populations), differences in baseline sodium intake (which modulates the renin-angiotensin system), and differences in gut microbiome composition affecting peptide metabolism.
For the broader category of food-derived blood pressure peptides, lactotripeptides remain the most extensively studied class. The casein-derived ACE inhibitory peptide literature extends beyond IPP and VPP to include longer peptide sequences with different binding characteristics. Lactotripeptides are the starting point, not the final word, on dairy peptides and cardiovascular health.
The Bottom Line
IPP and VPP are milk casein-derived tripeptides that inhibit ACE and stimulate endothelial nitric oxide production. Meta-analyses of clinical trials show an average systolic blood pressure reduction of -3.73 mmHg, but the effect is heavily population-dependent: approximately -7 mmHg in Asian populations versus -1 mmHg in European populations. Japanese clinical trials consistently demonstrate meaningful reductions in subjects with mild hypertension. EFSA rejected health claims for European populations. New evidence suggests casein-derived peptides also reshape gut microbiota, potentially contributing to blood pressure effects through a microbiome-mediated pathway. Bioavailability questions remain about whether enough intact peptide reaches the circulation for direct ACE inhibition.